Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25033947 | 0.83 | CA2 (0.36) | KDM4DJAK2JAK1JAK3 | |
| SCHEMBL25031530 | 0.81 | KDM4D (0.32) | KDM4D | |
| SCHEMBL22012969 | 0.81 | NLRP3 (0.33) | — | |
| SCHEMBL22012726 | 0.79 | JAK2 (0.31) | KDM4DJAK2JAK1JAK3 | |
| SCHEMBL31564466 | 0.77 | ADORA2A (0.35) | KDM4D | |
| SCHEMBL31564374 | 0.77 | HSD11B1 (0.34) | KDM4DKAT6AKAT8 | |
| SCHEMBL31564424 | 0.76 | PNMT (0.35) | KDM4D | |
| SCHEMBL31563993 | 0.76 | HSD11B1 (0.33) | KDM4DKAT6AKAT8 | |
| SCHEMBL31563832 | 0.76 | HSD11B1 (0.33) | KDM4D | |
| SCHEMBL31563996 | 0.76 | HSD11B1 (0.33) | KDM4DKAT6AKAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | KDM4D 4695/4885KAT6A 2961/4885KAT8 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.